{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:56:16Z","timestamp":1784094976973,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Liver fibrosis is a pathological condition in response to chronic liver injuries. Currently, there is no Food and Drug Administration (FDA) approved pharmacotherapy for liver fibrosis. Advances in understanding hepatic fibrogenesis have led to the development of anti-fibrotic agents, and some of them have shown promise in phase 3 and above clinical trials. However, adverse drug reactions (ADRs) associated with emerging anti-fibrotic agents may hinder their efficacy and clinical applicability. This study assessed ADRs associated with anti-fibrotic agents as reported in the World Health Organization (WHO) VigiAccess database and compared the adverse reaction characteristics of these agents for optimizing therapeutic strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A detailed search was conducted on <jats:ext-link>ClinicalTrial.gov<\/jats:ext-link> to identify phase 3 or 4 clinical trials involving hepatic anti-fibrotic agents. The ADR reports were retrieved from the WHO-VigiAccess database, with data categorized by demographic characteristics, geographic distribution, and System Organ Classes (SOCs). The most frequently reported ADRs were identified through descriptive analysis. Disproportionality analysis, measured by reporting odd ratio (ROR) and proportional reporting ratio (PRR), was performed to evaluate ADRs related to gastrointestinal disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Five hepatic anti-fibrotic agents (empagliflozin, liraglutide, candesartan, obeticholic acid, and resmetirom) were identified. A total of 130,567 ADR reports were analyzed, with empagliflozin, liraglutide, and candesartan showing significantly higher ADRs. The most frequently reported SOCs included gastrointestinal disorders (29.44%), general disorders (24.12%), and nervous system disorders (14.42%). Liraglutide demonstrated a higher risk of gastrointestinal ADRs (ROR: 4.629, 95% CI: 4.517\u20134.744; PRR: 3.566, 95% CI: 3.492\u20133.642) compared to the other agents. Severe ADRs were reported in empagliflozin, such as ketoacidosis and infections, while liraglutide was associated with pancreatitis and candesartan with acute kidney injury. Serious ADR rates varied, with candesartan reporting the highest proportion (7.28%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>While hepatic anti-fibrotic agents showed promise in addressing liver fibrosis, their ADR profiles underscore the importance of pharmacovigilance and personalized treatment approaches. Future efforts should focus on improving the pharmacovigilance system, expanding population diversity in trials, and conducting ongoing research and extensive post-marketing surveillance.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1534628","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:13:59Z","timestamp":1737702839000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials: a descriptive analysis of the WHO-VigiAccess database"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuwei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/s0140-6736(15)00803-x","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"Jama"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2337\/diabetes.53.5.1187","article-title":"One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e022577","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","volume":"9","author":"Donnan","year":"2019","journal-title":"BMJ Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B7","unstructured":"FDA approves first treatment for patients with liver scarring due to fatty liver disease\n          \n          \n          2024"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 inhibitors and the diabetic kidney","volume":"39","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.2215\/CJN.03060319","article-title":"Association of acute increases in plasma creatinine after renin-angiotensin blockade with subsequent outcomes","volume":"14","author":"Fu","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/s0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/j.1478-3231.2012.02774.x","article-title":"Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - a randomized open-label controlled study","volume":"32","author":"Kim","year":"2012","journal-title":"Liver Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"170057","DOI":"10.1183\/16000617.0057-2017","article-title":"Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis","volume":"26","author":"Lancaster","year":"2017","journal-title":"Eur. Respir. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"B19","doi-asserted-by":"publisher","first-page":"100853","DOI":"10.1016\/j.lanepe.2024.100853","article-title":"Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial","volume":"39","author":"Papamargaritis","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"B20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","article-title":"Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Parola","year":"2019","journal-title":"Mol. Asp. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s12072-020-10069-3","article-title":"Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study","volume":"14","author":"Poo","year":"2020","journal-title":"Hepatol. Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/s0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000980","article-title":"Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: results of multimodality assessment using both conventional and digital pathology","author":"Ratziu","year":"2024","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/diseases8020014","article-title":"SGLT2 inhibitors: the star in the treatment of type 2 diabetes?","volume":"8","author":"Saisho","year":"2020","journal-title":"Diseases"},{"key":"B26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/hc4101.096153","article-title":"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the council on the kidney in cardiovascular disease and the council for high blood pressure research of the American heart association","volume":"104","author":"Schoolwerth","year":"2001","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"155657","DOI":"10.1016\/j.metabol.2023.155657","article-title":"SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis","volume":"146","author":"Shen","year":"2023","journal-title":"Metabolism"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/dom.15399","article-title":"Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: a real-world data analysis","volume":"26","author":"Takahashi","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"935180","DOI":"10.3389\/fendo.2022.935180","article-title":"Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes","volume":"13","author":"Tan","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1517\/13543784.16.2.231","article-title":"Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus","volume":"16","author":"Vilsb\u00f8ll","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/s0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1534628\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:14:06Z","timestamp":1737702846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1534628\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":35,"alternative-id":["10.3389\/fphar.2025.1534628"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1534628","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"article-number":"1534628"}}